Clinical Trials

502 enrolled 18 charts 2 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03332017 2026-02-18

ROSEWOOD

217 enrolled 23 charts 2 FDA

Lymphoma, Follicular

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 2 FDA

Various Advanced Cancer

NCT02000622 2026-02-13

OlympiAD

302 enrolled 26 charts 2 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03275285 2026-02-09

IKEMA

302 enrolled 38 charts 2 FDA

Multiple Myeloma

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 2 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 2 FDA

Carcinoma, Renal Cell

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT04744831 2026-01-14

DESTINY-CRC02

122 enrolled 21 charts 2 FDA

Colorectal Neoplasms

NCT02296125 2026-01-09

FLAURA

674 enrolled 21 charts 2 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 2 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 2 FDA

657 enrolled 57 charts 5 FDA

Carcinoma, Non-Small-Cell Lung

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

Carcinoma, Hepatocellular

NCT03105336 2025-12-23

ZUMA-5

159 enrolled 27 charts 2 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT03180736 2025-12-19

EMN14

304 enrolled 19 charts 2 FDA

Multiple Myeloma

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

186 enrolled 14 charts 2 FDA

Graft vs Host Disease, Neoplasms

NCT03615326 2025-12-11

MK-3475-811

738 enrolled 22 charts 7 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

438 enrolled 40 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 4 FDA

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 5 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT03391466 2025-12-01

ZUMA-7

359 enrolled 27 charts 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT01358877 2025-11-28

APHINITY

4,804 enrolled 45 charts 2 FDA

Breast

Breast Neoplasms

NCT03201965 2025-11-26

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

416 enrolled 28 charts 5 FDA

Amyloidosis

NCT04644237 2025-11-21

DESTINY-LUNG02

152 enrolled 22 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT02743494 2025-11-18

CheckMate 577

794 enrolled 13 charts 2 FDA

Advanced Cancer

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 2 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT02060188 2025-11-06

CheckMate142

385 enrolled 17 charts 4 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04472429 2025-11-03

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

308 enrolled 17 charts 3 FDA

Anus Neoplasms, Carcinoma, Squamous Cell

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 2 FDA

Metastatic Hormone Sensitive Prostate Cancer

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

737 enrolled 30 charts 2 FDA

Multiple Myeloma

NCT03568461 2025-10-07

ELARA

98 enrolled 9 charts 2 FDA

Lymphoma, Follicular, Recurrence

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 3 FDA

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03778931 2025-09-15

EMERALD